atients needing treatment Novo Nordisk ® Data from SUSTAIN FORTE Semaglutide 2.0 mg showed superior HbA 1c reduction with more patients reaching target 1 versus semaglutide 1.0 mg Semaglutide 2.0 mg appeared to have a safe and well-tolerated profile Gastrointestinal adverse events were similar for semaglutide 1.0 mg and 2.0 mg Label expansion application approved in the US, JP and the EU
Download PDF file